More FDA Meetings Postponed, Canceled due to Coronavirus

Following an announcement last week that the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) would be cancelling, postponing or virtually hosting its upcoming meetings in light of the coronavirus disease (COVID-19) outbreak, the agency now says it will do so for “all non-essential meetings” through April.

As of Wednesday, the World Health Organization (WHO) says there are more than 200,000 cases of COVID-19 and more than 8,000 deaths from the disease globally. In the US, the Centers for Disease Control and Prevention (CDC) has confirmed more than 7,000 cases while media reports on Tuesday said the number of deaths in the country from the virus have passed 100.

“The FDA, like other governmental agencies, is taking the necessary steps to ensure the agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the COVID-19 public health emergency,” FDA writes, noting that it will reassess upcoming meetings in future months and host meetings virtually where possible.

Many of the meetings have been updated to include a statement that they have been postponed or made virtual only due to the coronavirus outbreak. For some meetings, the relevant registration page notes the change. So far FDA has not indicated when any of the meetings may be rescheduled.

Some of the affected CDER meetings were also listed in a Federal Register notice published Wednesday.

Meeting	Original Date(s)	Outcome
Public Meeting on Patient-Focused Drug Development for Stimulant Use Disorder	10 March 2020	Postponed
Meeting of the Nonprescription Drugs Advisory Committee	11 March 2020	Postponed
CDER SEND Common Issues and Policy Update	20 March 2020	Postponed
Identification of Concepts and Terminology for Multi-Component Biomarkers	23 March 2020	Postponed
Modernizing FDA’s Data Strategy	27 March 2020	Postponed
Public Meeting on Patient-Focused Drug Development for Vitiligo	30 March 2020	Postponed
Using Patient Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond	31 March 2020	Postponed
Food and Drug Administration’s Communications About the Safety of Medical Devices	1 April 2020	Postponed
Blood Products Advisory Committee Meeting	2-3 April 2020	Postponed
Health Canada and FDA Joint Public Consultation on International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use	3 April 2020	Virtual
Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027	7 April 2020	Postponed
Public Workshop - Towards Good Simulation Practices in Health Technologies	13-15 April 2020	Postponed
Regulatory Education for Industry Generic Drugs Forum	15-16 April 2020	Virtual
Circulatory System Devices Panel of the Medical Devices Advisory Committee	16 April 2020	Postponed
Scientific and Ethical Considerations for the Inclusion of Pregnant Women in Clinical Trials	16 April 2020	Postponed
12th Annual FDA Sentinel Public Workshop	20-21 April 2020	Postponed
Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standard	22 April 2020	Postponed

For some upcoming meetings it is unclear whether they have been postponed or canceled, as the meeting pages have not been updated.

Meeting	Date(s)
Public Meeting to Prepare for the International Cooperation on Cosmetics Regulation (ICCR-14)	14 April 2020
Webinar - Clinical Laboratory Improvement Amendments (CLIA) Waiver Applications Final Guidances	14 April 2020
Webinar - 510(k) Third Party Review Program: Final Guidance	16 April 2020
Webinar - 510(k) Third Party Review Program: Final Guidance	16 April 2020
Meeting of the Pulmonary-Allergy Drugs Advisory Committee	21 April 2020
Medical Imaging Drugs Advisory Committee Meeting	23 April 2020
Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee Meeting	23-24 April 2020
Pediatric Advisory Committee Meeting	29 April 2020

Return to listing